NCT03603223View on ClinicalTrials.gov

Pembrolizumab in Treating Participants With Leukoplakia

PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 3, 2019

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
ErythroleukoplakiaLeukoplakiaVerrucous Oral Leukoplakia
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (3)

90033

NOT_YET_RECRUITING

USC / Norris Comprehensive Cancer Center, Los Angeles

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

92093

NOT_YET_RECRUITING

UC San Diego Moores Cancer Center, La Jolla

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER